In this article, we break down the Top 5 Small-Cap Biotech Stocks That Could Surge 100%. For investors looking for the complete list, you can explore our full report on the Top 10 Small-Cap Biotech Stocks That Could Surge 100%.
5. Trevi Therapeutics Inc. (NASDAQ:TRVI)
Trevi Therapeutics, Inc. (NASDAQ: TRVI) ranks fifth on the list and remains one of the more compelling names among clinical-stage small-cap biotech stocks. Trevi Therapeutics, Inc. (NASDAQ: TRVI) is developing Haduvio for serious neurologic and respiratory-related conditions, including chronic cough in idiopathic pulmonary fibrosis and chronic pruritus. These are not minor conditions. Chronic cough linked to idiopathic pulmonary fibrosis can be deeply disruptive for patients, while chronic pruritus can severely affect quality of life.
The key reason Trevi Therapeutics, Inc. (NASDAQ: TRVI) deserves attention is its cash runway. The company completed a follow-on offering with about $162 million in net proceeds, extending its expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough. In the small-cap biotech world, that is a major advantage. Many clinical-stage companies live under constant financing pressure, but Trevi Therapeutics, Inc. (NASDAQ: TRVI) has given itself more time to execute.
Cash runway matters because clinical trials are expensive, regulatory preparation takes time, and commercialization planning can drain resources long before revenue arrives. When a company like Trevi Therapeutics, Inc. (NASDAQ: TRVI) can say it has runway into 2030, investors may view the story differently. It reduces near-term dilution concerns and allows the market to focus more on clinical progress rather than survival financing.
Haduvio is the center of the story. Trevi Therapeutics, Inc. (NASDAQ: TRVI) is targeting conditions where patients need better options, and that gives the company a strong SEO position across neurological biotech stocks, respiratory biotech stocks, chronic cough treatment stocks, IPF-related cough stocks, chronic pruritus biotech stocks, and small-cap biotech stocks with FDA potential. The disease areas may not be as widely discussed as cancer, but that can actually make the opportunity more interesting. Underfollowed areas of medicine can sometimes produce meaningful value if a company solves a real patient problem.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is also attractive because its thesis is relatively clear. The company has a lead drug candidate, defined target indications, a strengthened cash position, and a potential regulatory path. That does not guarantee success, but it gives investors a framework to evaluate the company. In biotech, clarity is valuable because too many small companies have scattered pipelines that make the story hard to understand.
The risk is that Trevi Therapeutics, Inc. (NASDAQ: TRVI) remains clinical-stage. Until a drug is approved and commercialized, the company is still dependent on trial success and regulatory outcomes. Investors need to monitor data quality, safety results, enrollment, FDA feedback, and the size of the addressable market.
Even with those risks, Trevi Therapeutics, Inc. (NASDAQ: TRVI) earns a strong position on this list because of its cash runway and focused pipeline. For investors looking for small-cap biotech stocks with catalysts, biotech stocks with strong cash positions, and clinical-stage companies targeting serious unmet needs, Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a name worth watching.
Click next to see the following stock...
